Trials in Florida.
118 APOE4-relevant Alzheimer’s trials run in Florida — 55 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Stratified by APOE4 genotype specificallyNCT01211782AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
This trial tests AC-1204, an oral ketogenic compound made from caprylic triglyceride, in people with mild to moderate Alzheimer's disease. The idea is that…
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Built exclusively for APOE4 homozygotesNCT03634007Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
This Phase 1 trial is testing LX1001, a gene therapy delivered into the spinal fluid, in people who carry two copies of APOE4 and already have…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- Exclusively enrolls APOE4 homozygotesNCT03887741Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression
This trial is testing whether it is safe to give plasma from young APOE3 carriers to people who are APOE4 homozygous and already showing mild cognitive…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- Explicitly welcomes APOE4 carriersNCT06043700A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
This is a screening study, not a treatment trial. Researchers are using blood tests to find people who may have high levels of amyloid protein in the brain — a…
- APOE4/4 only, closed to new enrolleesNCT06304883Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
This is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…
- 4/4 carriers excluded, one copy may qualifyNCT07688213A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing SAR448851, a once-daily oral pill, in people with early Alzheimer's disease who have confirmed amyloid buildup in the brain.…
- APOE4 enrolled, response may differNCT00348140Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
- Enrolled carriers, prior data unfavorableNCT00348309Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
- APOE4 stratified, suggests less benefitNCT00428090Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…
- Closed trial, APOE4 stratifiedNCT00550420Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
This Phase 3 trial tested rosiglitazone XR, a diabetes drug, in people with mild-to-moderate Alzheimer's disease. It was an open-label extension study, meaning…
- Open to carriers, not 4-specificNCT00710684A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
This trial tested SB-742457, an experimental drug added on top of donepezil, the standard Alzheimer's medication, in people with mild-to-moderate Alzheimer's…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Heart trial, genotype not relevantNCT02884206Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
- Observational only, no treatment involvedNCT02951598A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
- Discontinued trial, not APOE4-specificNCT02972658A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
- Open to carriers, not 4-specificNCT03108846Escitalopram for Agitation in Alzheimer's Disease
This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…
- Genotype-blind, not APOE4-specificNCT03135327Clinical Applications of Advanced Ophthalmic Imaging
This study is testing whether advanced eye-imaging tools — including OCT scans and retinal imaging — can detect changes in the eyes of people with conditions…
- Open to carriers, not 4-specificNCT03507257Longitudinal Early-onset Alzheimer's Disease Study Protocol
LEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…
- Open to carriers, not 4-specificNCT03556280Multi-Center Study of Sensory Stimulation to Improve Brain Function
This trial tests a device called the GammaSense Stimulation System, which delivers sensory stimulation at a specific brain rhythm frequency called gamma.…
- Open to carriers, not 4-specificNCT03649724The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
The LUCINDA Trial is testing whether leuprolide acetate, a hormone-suppressing drug already used for other conditions, can slow cognitive decline when added to…
- Open to carriers, not 4-specificNCT03657745Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy
This trial is testing an iPad app called AlzLife that flashes light at 40 times per second (40Hz) combined with cognitive exercises. The idea is that this…
- No relevance to APOE4 carriersNCT03698747Myelin Imaging in Concussed High School Football Players
This study uses a specialized MRI technique called McDESPOT to look at myelin — the protective coating around nerve fibers in the brain — in high school…
- Open to carriers, not 4-specificNCT03848312Preventing Alzheimer's With Cognitive Training
This Phase 3 trial is testing whether a specific type of computerized brain training — called speed of processing training — can delay the onset of mild…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- Family history required, genotype not specifiedNCT04018092The Revitalize Study in Older Adults at Risk for Alzheimer's Disease
This trial is testing whether a light-based device — near-infrared light delivered through the scalp and nose, called photobiomodulation — can support brain…
- Open to carriers, genotype not trackedNCT04098666Metformin in Alzheimer's Dementia Prevention
This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…
- Monitoring tool, genotype not relevantNCT04114994Longitudinal Cognitive Assessment by BoCA
This study is testing a self-administered online cognitive test called BoCA — the Boston Cognitive Assessment. Researchers want to see how well it tracks…
- Open to carriers, not 4-specificNCT04148391NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
This trial is testing NYX-458, an experimental oral drug, against a placebo in people who have mild cognitive impairment or mild dementia caused by Parkinson's…
- Open to carriers, genotype not trackedNCT04171323The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
This trial is testing different combinations of computerized brain exercises to see which combination best helps older adults with mild cognitive impairment…
- Unrelated to APOE4 genotypeNCT04220021Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD
This trial is testing whether metformin, a widely used diabetes drug, is safe for people with a specific genetic form of ALS and frontotemporal dementia caused…
- Open to carriers, not 4-specificNCT04262206Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
- FTLD-focused, not APOE4-relevantNCT04363684ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
- Wrong condition, not APOE4-relevantNCT04408625Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
This trial is testing LY3884963, a biological therapy delivered directly into the fluid around the brain and spine, in people who have frontotemporal dementia…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Genotype collected, carriers not excluded yetNCT04639050Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
This Phase 1 trial is testing a drug called RO7126209 — given by IV infusion — in people with early to moderate Alzheimer's who have confirmed amyloid buildup…
- Open to carriers, genotype not consideredNCT04679441A Novel Computer-Based Functional Skills Assessment and Training Program
This trial is testing a computer-based program designed to help older adults practice everyday tasks like managing finances and medications. Researchers are…
- No Alzheimer's or APOE4 relevanceNCT04793776Manage Emotions to Reduce Aggression (MERA)
This trial tests a 3-session behavioral therapy called MERA — Manage Emotions to Reduce Aggression — against a control therapy in veterans with PTSD who…
- Open to carriers, not 4-specificNCT04838301Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
This trial is testing allopregnanolone — a naturally occurring brain steroid — to see whether it slows or improves cognition in people with mild Alzheimer's…
- Lifestyle study, genotype not requiredNCT04855630Combating Alzheimer's Through Sleep and Exercise
This trial is testing whether a combination of structured exercise and monitored sleep — tracked with a DREEM 2 headband and a Fitbit — can affect dementia…
- Caregiver study, genotype not relevantNCT04896775NiteCAPP: Web-based Interventions for Insomnia in Rural Dementia Caregivers
This trial is testing two web-based behavioral programs, NiteCAPP CARES and NiteCAPP SHARES, designed to help dementia caregivers in rural areas sleep better.…
- Observational only, genotype not specifiedNCT04916210Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…
- Genetic study, carriers likely relevantNCT05010603Late Onset Alzheimer's Disease
This study collects blood samples and runs memory and thinking tests to look for genes that influence who gets Alzheimer's disease. It focuses on families…
- LBD trial, genotype not relevantNCT05014971Telehealth in Lewy Body Dementia
This trial tests whether telehealth video visits can improve access to specialized, team-based care for people with Lewy body dementia. Instead of traveling to…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.